United Therapeutics Corporation (NASDAQ:UTHR) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD.
On January31, 2019, United Therapeutics Corporation (the “Company”) issued a press release disclosing data from its FREEDOM-EV clinical study of Orenitram® (treprostinil) Extended-Release Tablets, including data shared during an oral presentation at the Pulmonary Vascular Research Institute (“PVRI”) Annual World Congress on Pulmonary Vascular Disease in Barcelona, Spain. A copy of the press release, as well as a copy of the slides presented at the PVRI presentation, are being furnished as Exhibit99.1 and Exhibit99.2 hereto, respectively, and are incorporated herein by reference.
The information in this Item 7.01 and the related Item 9.01, including Exhibit99.1 and Exhibit99.2 attached hereto, are being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act as amended, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
UNITED THERAPEUTICS Corp Exhibit
EX-99.1 2 a19-3803_1ex99d1.htm EX-99.1 Exhibit 99.1 Contact: James Edgemond Phone: (301) 608-9292 E-mail: [email protected] SURVIVAL DATA FROM FREEDOM-EV STUDY OF ORENITRAM PRESENTED AT THE PULMONARY VASCULAR RESEARCH INSTITUTE ANNUAL WORLD CONGRESS Silver Spring,…
To view the full exhibit click here
About United Therapeutics Corporation (NASDAQ:UTHR)
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb). Its Prostacyclin Analogues lead product is Remodulin (treprostinil) Injection. It also includes Tyvaso (treprostinil) Inhalation Solution and Orenitram (treprostinil) Extended-Release Tablets. Its subsidiary is developing another oral prostacyclin analogue for the treatment of pulmonary arterial hypertension (PAH) called esuberaprost. Its PDE-5 inhibitor is Adcirca (tadalafil) tablets are indicated for the treatment of PAH. Its Unituxin (dinutuximab) Injection in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2 and 13-cis-retinoic acid is indicated for the treatment of pediatric patients with neuroblastoma.
